By contrast, there was no statistical significance in the serum MMP-10 concentration (Fig. 3d) between BPH (484.7 ± 157.7 pg/ml) and prostate cancer patients with either low-grade tumors (810.7 ± 552.2 pg/ml) or high-grade tumors (1069.3 ± 1197.3 pg/ml). This evidence concerns the gene MMP10 and benign prostatic hyperplasia.